| Serial Number | 98390037 |
| Word Mark | LYMTELBA |
| Filing Date | Saturday, February 3, 2024 |
| Status | 686 - PUBLISHED FOR OPPOSITION |
| Status Date | Tuesday, May 20, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, May 20, 2025 |
| Goods and Services | Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical and biological preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use, namely, for the treatment of neuropsychiatric disorders; Pharmaceutical preparations for human use, namely, therapeutic radiopharmaceutical preparations for the treatment of cancer and solid tumors, diagnostic radiopharmaceutical preparations, diagnostic agents, preparations and substances for medical purposes; Pharmaceutical preparations for human use, namely, radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer, radio-isotope markers for therapeutic or diagnostic use. |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, March 7, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Celgene Corporation |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Princeton, NJ 08543 |
| Party Name | Celgene Corporation |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Princeton, NJ 08543 |
| Event Date | Event Description |
| Wednesday, February 7, 2024 | NEW APPLICATION ENTERED |
| Wednesday, August 28, 2024 | ASSIGNED TO EXAMINER |
| Tuesday, September 3, 2024 | NON-FINAL ACTION E-MAILED |
| Tuesday, September 3, 2024 | NON-FINAL ACTION WRITTEN |
| Tuesday, September 3, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, December 3, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, December 3, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, December 3, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, January 8, 2025 | NON-FINAL ACTION E-MAILED |
| Wednesday, January 8, 2025 | NON-FINAL ACTION WRITTEN |
| Wednesday, January 8, 2025 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, April 1, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, April 1, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, April 1, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, March 7, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, April 23, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, May 14, 2025 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, May 20, 2025 | PUBLISHED FOR OPPOSITION |
| Tuesday, May 20, 2025 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |